GlassScriptPhysician profile
Brenda Lee Houdeshell
NPI 1487396396
$1,008.38
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $549 · 2024: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.91 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $128.51 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $99.33 | 2023-2024 | Prolia, Evenity, Tepezza |
| Dexcom, INC. | $91.98 | 2023-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $66.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2023-2024 | Jardiance |
| Kyowa Kirin, INC. | $49.64 | 2023-2024 | Crysvita |
| Tandem Diabetes Care, INC. | $45.61 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $44.40 | 2023-2024 | |
| Antares Pharma, INC. | $41.35 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $35.42 | 2023-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $24.90 | 2024 | |
| Ibsa Pharma INC. | $21.48 | 2023 | Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $21.44 | 2024 | |
| Insulet Corporation | $21.27 | 2024 | Omnipod |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $20.90 | 2023 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $19.44 | 2023 | Strensiq |
| Medtronic, INC. | $16.24 | 2023 | Inpen Smart Insulin Delivery System |
| Glaxosmithkline, LLC. | $16.02 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Houdeshell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.